Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC70 | ZSTK474 | 2 | 72 | 3.2 | 673.8 | 2409.0 | 722.8 | 0.505 | -0.040 | 0.280 | 1.737 | HCC70 ZSTK474 0 2 72 |
| HCC70 | AS605240 | 3 | 72 | 3.2 | 1585.8 | 2821.5 | 517.3 | 0.505 | 0.580 | 0.562 | 2.447 | HCC70 AS605240 0 3 72 |
| BT-549 | MK2206 | 3 | 72 | 3.2 | 5138.0 | 3781.8 | 1175.8 | 0.505 | 1.400 | 1.360 | 1.685 | BT549 MK2206 0 3 72 |
| HCC70 | AZD8055 | 3 | 72 | 3.2 | 1558.3 | 2811.8 | 517.3 | 0.505 | 0.571 | 0.554 | 2.442 | HCC70 AZD8055 0 3 72 |
| BT-20 | CAL-101 | 2 | 72 | 3.2 | 2930.8 | 3469.3 | 1018.6 | 0.505 | 0.818 | 0.845 | 1.768 | BT20 CAL101 0 2 |
| BT-20 | PIK-93 | 1 | 72 | 3.2 | 2878.0 | 5875.8 | 1443.3 | 0.505 | 0.406 | 0.490 | 2.025 | BT20 PIK93 0 1 |
| BT-20 | CAL-101 | 1 | 72 | 3.2 | 5408.0 | 6240.0 | 1443.3 | 0.505 | 0.869 | 0.867 | 2.112 | BT20 CAL101 0 1 |
| BT-20 | ZSTK474 | 3 | 72 | 3.2 | 583.5 | 3579.5 | 586.9 | 0.505 | -0.002 | 0.163 | 2.609 | BT20 ZSTK474 0 3 |
| BT-20 | Dactolisib | 1 | 72 | 3.2 | 900.5 | 5998.3 | 1443.3 | 0.505 | -0.205 | 0.150 | 2.055 | BT20 BEZ235 0 1 |
| BT-20 | PIK-93 | 2 | 72 | 3.2 | 1319.8 | 3542.3 | 1018.6 | 0.505 | 0.155 | 0.373 | 1.798 | BT20 PIK93 0 2 |
| BT-20 | Sirolimus | 2 | 72 | 3.2 | 1394.3 | 3606.8 | 1018.6 | 0.505 | 0.188 | 0.387 | 1.824 | BT20 Rapamycin 0 2 |
| BT-20 | GDC-0980 | 2 | 72 | 3.2 | 420.0 | 3217.8 | 1018.6 | 0.505 | -0.414 | 0.131 | 1.659 | BT20 GDC0980 0 2 |
| BT-20 | Everolimus | 2 | 72 | 3.2 | 1212.8 | 3213.5 | 1018.6 | 0.505 | 0.111 | 0.377 | 1.658 | BT20 Everolimus 0 2 |
| BT-20 | AZD-6482 | 1 | 72 | 3.2 | 2032.7 | 5948.8 | 1443.3 | 0.505 | 0.182 | 0.342 | 2.043 | BT20 AZD6482 0 1 |
| BT-20 | KIN001-244 | 2 | 72 | 3.2 | 2975.3 | 3407.5 | 1018.6 | 0.505 | 0.850 | 0.873 | 1.742 | BT20 KIN001-244 0 2 |
| BT-20 | WYE-125132 | 2 | 72 | 3.2 | 831.0 | 3613.5 | 1018.6 | 0.505 | -0.105 | 0.230 | 1.827 | BT20 WYE125132 0 2 |
| BT-549 | Torin2 | 1 | 72 | 3.2 | 1007.0 | 5306.0 | 1554.9 | 0.505 | -0.218 | 0.190 | 1.771 | BT549 Torin2 0 1 72 |
| BT-549 | Torin2 | 3 | 72 | 3.2 | 733.3 | 3597.8 | 1175.8 | 0.505 | -0.254 | 0.204 | 1.613 | BT549 Torin2 0 3 72 |
| BT-549 | WYE-125132 | 3 | 72 | 3.2 | 1228.0 | 3719.8 | 1175.8 | 0.505 | 0.027 | 0.330 | 1.662 | BT549 WYE125132 0 3 72 |
| BT-549 | XL147 | 3 | 72 | 3.2 | 3779.0 | 4015.3 | 1175.8 | 0.505 | 0.933 | 0.941 | 1.772 | BT549 XL147 0 3 72 |
| BT-20 | Pictilisib | 2 | 72 | 3.2 | 927.8 | 3416.0 | 1018.6 | 0.505 | -0.052 | 0.272 | 1.746 | BT20 GDC0941 0 2 |
| BT-20 | Sirolimus | 1 | 72 | 3.2 | 3597.5 | 5856.5 | 1443.3 | 0.505 | 0.571 | 0.614 | 2.021 | BT20 Rapamycin 0 1 |
| BT-20 | AS605240 | 1 | 72 | 3.2 | 5187.0 | 6371.0 | 1443.3 | 0.505 | 0.817 | 0.814 | 2.142 | BT20 AS605240 0 1 |
| HCC70 | GDC-0980 | 3 | 72 | 3.2 | 814.0 | 2773.8 | 517.3 | 0.505 | 0.206 | 0.293 | 2.423 | HCC70 GDC0980 0 3 72 |
| HCC70 | Pictilisib | 3 | 72 | 3.2 | 992.8 | 2827.0 | 517.3 | 0.505 | 0.305 | 0.351 | 2.450 | HCC70 GDC0941 0 3 72 |